CETP

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR

Cat.No.	Product Name	Information	Product Use Citations
S2748	Anacetrapib (MK-0859)	Anacetrapib (MK-0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM. It increases HDL-C and decreases LDL-C, and does not increase aldosterone or blood pressure. This compound is in Phase 3.	Circulation, 2021, 143(9):921-934 J Phys Chem B, 2016, 120(33):8254-63 Atherosclerosis, 2014, 235(2):449-62
S2792	Torcetrapib	Torcetrapib (CP-529414) is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3.	J Immunother Cancer, 2024, 12(11)e009805
S2772	Dalcetrapib (JTT-705)	Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol. This compound is in Phase 3.	Atherosclerosis, 2014, 235(2):449-62
S2925	Evacetrapib (LY2484595)	Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.
E1561	Obicetrapib	Obicetrapib (TA-8995, AMG-899, DEZ-001) is an inhibitor of Cholesteryl Ester Transfer Protein (CETP) that significantly reduces non-HDL cholesterol (non-HDL-C) and lipoprotein(a) levels while increasing high-density lipoprotein cholesterol (HDL-C). It also has the potential to reduce major adverse cardiovascular events.